Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.86 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.68 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.68 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.68 |
| ▸ | BCR | P11274 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31734730 | 0.99 | ABL1 (0.85) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL15510693 | 0.93 | ABL1 (0.87) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL588662 | 0.93 | ABL1 (1.00) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL15144975 | 0.89 | ABL1 (0.70) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL9610801 | 0.89 | ABL1 (0.70) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL10207540 | 0.87 | ABL1 (0.79) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL9610977 | 0.87 | ABL1 (1.00) | ABL1 | |
| SCHEMBL30010196 | 0.87 | ABL1 (1.00) | ABL1 | |
| SCHEMBL9610965 | 0.86 | ABL1 (1.00) | ABL1DDR1DDR2NTRK1NTRK3 | |
| SCHEMBL15061735 | 0.86 | ABL1 (0.79) | ABL1DDR1DDR2NTRK1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | claimed |
| EP-2841062-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2015-03-04 | — | — | EP | claimed |
| US-8778942-B2 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2694064-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Ariad Pharmaceuticals, Incorporated (US) | 2014-02-12 | — | — | EP | claimed |
| EP-2694066-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD Pharmaceuticals, Inc (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2013162727-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| WO-2013101281-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| WO-2012139027-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | claimed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3747441-A1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD Pharmaceuticals, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3417912-B1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1973545-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ABL1 122/4885DDR1 1119/4885DDR2 1456/4885 |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885DDR1 4848/4885DDR2 4802/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885DDR1 2431/4885DDR2 3529/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885DDR1 4853/4885DDR2 4239/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | ABL1 4036/4885DDR1 4786/4885DDR2 4731/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885DDR1 4853/4885DDR2 4239/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ABL1 122/4885DDR1 1119/4885DDR2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.